'Lovell-Badge, though, mostly worries that genome editing will become the preserve of the wealthy, given that current therapies are estimated to cost upwards of six figures per patient. “The question of equitable access is a huge one,” Lovell-Badge tells me. “How do we get costs down? It’s a challenge for scientists, for economists and for everyone.”

https://www.ft.com/content/8b65ddfb-b4a3-444c-93ca-73dfb881399e